🚀 VC round data is live in beta, check it out!
Haisco Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Haisco Pharmaceutical and similar public comparables like Mankind Pharma, Vaxcyte, Huadong Medicine, Praxis Precision Medicines and more.
Haisco Pharmaceutical Overview
About Haisco Pharmaceutical
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Founded
2000
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$9B
Haisco Pharmaceutical Financials
Haisco Pharmaceutical reported last 12-month revenue of $730M and EBITDA of $123M.
In the same LTM period, Haisco Pharmaceutical generated $536M in gross profit, $123M in EBITDA, and $82M in net income.
Revenue (LTM)
Haisco Pharmaceutical P&L
In the most recent fiscal year, Haisco Pharmaceutical reported revenue of $643M and EBITDA of $86M.
Haisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $730M | XXX | $643M | XXX | XXX | XXX |
| Gross Profit | $536M | XXX | $458M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $123M | XXX | $86M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $82M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Haisco Pharmaceutical Stock Performance
Haisco Pharmaceutical has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Haisco Pharmaceutical's stock price is $8.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | -1.5% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHaisco Pharmaceutical Valuation Multiples
Haisco Pharmaceutical trades at 12.7x EV/Revenue multiple, and 75.6x EV/EBITDA.
EV / Revenue (LTM)
Haisco Pharmaceutical Financial Valuation Multiples
As of April 19, 2026, Haisco Pharmaceutical has market cap of $9B and EV of $9B.
Equity research analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haisco Pharmaceutical has a P/E ratio of 111.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 12.7x | XXX | 14.4x | XXX | XXX | XXX |
| EV/EBITDA | 75.6x | XXX | 108.4x | XXX | XXX | XXX |
| EV/EBIT | 95.2x | XXX | 195.6x | XXX | XXX | XXX |
| EV/Gross Profit | 17.3x | XXX | 20.3x | XXX | XXX | XXX |
| P/E | 111.9x | XXX | 241.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 139.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Haisco Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Haisco Pharmaceutical Margins & Growth Rates
Haisco Pharmaceutical's revenue in the last 12 month grew by 31%.
Haisco Pharmaceutical's rule of 40 is 74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haisco Pharmaceutical's rule of X is 143% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Haisco Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 90% | XXX | 207% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 74% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 143% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Haisco Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Haisco Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Praxis Precision Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Fosun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haisco Pharmaceutical M&A Activity
Haisco Pharmaceutical acquired XXX companies to date.
Last acquisition by Haisco Pharmaceutical was on XXXXXXXX, XXXXX. Haisco Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Haisco Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHaisco Pharmaceutical Investment Activity
Haisco Pharmaceutical invested in XXX companies to date.
Haisco Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Haisco Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Haisco Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Haisco Pharmaceutical
| When was Haisco Pharmaceutical founded? | Haisco Pharmaceutical was founded in 2000. |
| Where is Haisco Pharmaceutical headquartered? | Haisco Pharmaceutical is headquartered in China. |
| Is Haisco Pharmaceutical publicly listed? | Yes, Haisco Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Haisco Pharmaceutical? | Haisco Pharmaceutical trades under 002653 ticker. |
| When did Haisco Pharmaceutical go public? | Haisco Pharmaceutical went public in 2012. |
| Who are competitors of Haisco Pharmaceutical? | Haisco Pharmaceutical main competitors are Mankind Pharma, Vaxcyte, Huadong Medicine, Praxis Precision Medicines. |
| What is the current market cap of Haisco Pharmaceutical? | Haisco Pharmaceutical's current market cap is $9B. |
| What is the current revenue of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12 months revenue is $730M. |
| What is the current revenue growth of Haisco Pharmaceutical? | Haisco Pharmaceutical revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Haisco Pharmaceutical? | Current revenue multiple of Haisco Pharmaceutical is 12.7x. |
| Is Haisco Pharmaceutical profitable? | Yes, Haisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haisco Pharmaceutical? | Haisco Pharmaceutical's last 12 months EBITDA is $123M. |
| What is Haisco Pharmaceutical's EBITDA margin? | Haisco Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Haisco Pharmaceutical? | Current EBITDA multiple of Haisco Pharmaceutical is 75.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.